13 results about "Risk allele" patented technology

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

This invention belongs to the field of myopia prevention and control technology, and relates to a method, device, and medium for myopia prevention and control based on genetic and environmental factors. Based on myopia data of each blood relative of the user to be intervened, the variant sites in the myopia-related single nucleotide polymorphism genotype, and the number of risk alleles, a myopia genetic risk index is calculated. Based on the user's daily outdoor activity time, total daily eye use time, daily near-vision time, and daily low-light eye use time over several consecutive days, an outdoor activity stability index, a near-vision load index, and an eye use light stability index are calculated, thus obtaining an environmental myopia risk index. The axial length, refractive error, myopia genetic risk index, and environmental myopia risk index of the user to be intervened are input into an adaptive Bayesian myopia risk prediction model, which outputs the myopia risk change trajectory under different myopia intervention intensities, including the predicted mean and uncertainty interval, thereby obtaining a myopia intervention strategy.

This provides a means to accurately and easily determine an individual's genetic predisposition to vascular aging. [Solution] A method for determining the genetic risk of vascular aging, comprising the steps of: detecting alleles of single nucleotide polymorphisms (SNPs) at the 51st base of one or more sequences identified in (A) to (E) below from a DNA-containing sample taken from a subject; and determining that the subject is prone to developing symptoms related to vascular aging if the detected allele's base is a risk allele. (A)SNP:ID rs17108108 (B)SNP:ID rs2271987 (C)SNP:ID rs6470860 (D)SNP:ID rs2284972 (E)SNP:ID rs12028323

The application discloses a caries risk assessment method, device and storage medium, which are applied to the technical field of oral image processing, and the method acquires multi-source data corresponding to a caries sample to be evaluated, wherein the multi-source data at least includes oral image data and gene data; risk alleles of multiple gene sites related to caries susceptibility; the gene data is numerically encoded to obtain gene features; the oral image data is subjected to feature extraction to obtain oral image features; the gene features and the oral image features are subjected to feature fusion to obtain fusion features; and the fusion features are subjected to caries risk assessment to obtain a caries risk assessment result of the caries sample to be evaluated, so that the accuracy of caries risk assessment can be improved.

An IL33 antagonist, alone or in combination with an IL-4R antagonist, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyp in a subject having one or more risk alleles in the intron IL1RL1 variant rs1420101, in the IL33 variant rs1342326, both, or in variants of their linkage imbalance.

IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof. 20 24 22 02 14 30 S ep 2 02 4 A B S T R A C T 2 0 2 4 2 2 0 2 1 4 3 0 2 0 2 4 S e p

Described herein is a method of treating, ameliorating and / or preventing a kidney disease in a subject in need thereof. The method comprises performing a genomic editing in the subject to replace a risk allele of a kidney disease SNP with a reference allele; or adjusting the expression or activity of a kidney disease gene. Also described herein is a method of predicting the risk of kidney disease in a subject. The method comprises detecting the presence or absence of a risk allele of a kidney disease SNP in the subject

This invention relates to an adenovirus susceptibility risk assessment model and biomarkers, belonging to the field of gene analysis technology. The method for establishing this model includes the following steps: Susceptibility locus and susceptibility effect value analysis: obtaining whole-genome SNP locus data from adenovirus-infected and non-infected individuals, and analyzing them using the GWAS method to obtain the susceptibility loci for adenovirus infection and their corresponding susceptibility effect values; Establishment of an adenovirus susceptibility polygenic risk prediction model: calculating the adenovirus susceptibility polygenic risk score PRS using the formula: PRS = β1x1 + β2x2 + ... + β k x k +…+β n x n β represents the susceptibility effect value corresponding to the susceptibility locus obtained from GWAS analysis, x represents the number of risky allele mutations, n represents the total number of SNPs included in the PRS analysis model, and k represents each SNP included in the PRS analysis model. This adenovirus susceptibility risk assessment model, validated with sample groups from different data sources, can distinguish between adenovirus-susceptible populations and control groups, demonstrating the superior discriminative power of the model of this invention.

Methods of treating a patient suffering from an interleukin (IL) -33-mediated disorder and methods for determining whether a patient is at increased risk of suffering from an IL-33-mediated disorder or methods for determining whether a patient suffering from a disorder has an increased likelihood of responding to an anti-IL-33 therapy are provided.SOLUTION: A method for treating a patient suffering from asthma, the method comprising administering an IL-33 axis binding antagonist to the patient, wherein the patient's genotype has been determined to comprise at least one allele of a cluster 2 polymorphism defined elsewhere or an equivalent allele at a polymorphism in linkage disequilibrium therewith.SELECTED DRAWING: None

This invention belongs to the field of animal molecular breeding technology, specifically disclosing a SNP molecular marker associated with the trait of black peritoneum in chickens and its application. Through genome-wide association analysis, this invention obtained an SNP molecular marker that is highly significantly associated with the black peritoneum trait in yellow-feathered broilers. This marker, using the chicken GRCg7b genome as a reference, is located at position 120222 on chromosome 3, and is an A / T mutation with genotypes including AA, AT, and TT. Association analysis showed that this locus was highly significantly associated with the black peritoneum phenotype observed after slaughter at 11 weeks of age. The incidence of black peritoneum in individuals with the AA genotype was significantly lower than that of individuals with the AT and TT genotypes. A is the dominant allele reducing the occurrence of black peritoneum, and T is the risk allele for black peritoneum. This invention also provides specific primers for detecting this molecular marker and a marker-assisted selection method, enabling early, non-destructive, and precise selection for the black peritoneum trait, reducing slaughter defect rates, and improving the carcass quality and economic benefits of yellow-feathered broilers.

We have identified panels of proxy single nucleotide polymorphisms (SNPs) that are highly predictive of particular HLA risk alleles, and concordant across multi-ethnic populations. Accordingly, methods are provided involving clinical DNA testing for HLA panel markers to assess risk for life-threatening adverse drug reactions associated with the human leucocyte antigen (HLA) alleles HLA-B*57:01, HLA-B*15:02, HLA-A*31:01 and HLA-B*58:01. Methods of treating a subject with a drug associated with an adverse drug reaction (ADR) are provided. Based on the assessed risk to a subject for developing an adverse drug reaction in response to a drug, appropriate administrations of the drug can be made. In some embodiments of the method, the drug is administered when there is a low assessed risk of ADR in the subject. Alternatively, when there is a high assessed risk of ADR in the subject, a reduced dosage of the drug, or no drug, can be administered.

This invention relates to the fields of bioinformatics and immunogenetics, and discloses an HLA typing tool selection system, method, device, and medium based on a typing tool invocation agent. The method includes: acquiring second-generation sequencing data and Sanger sequencing data from patients with autoimmune diseases; having a typing tool invocation agent invoke several HLA typing tools to perform HLA typing analysis on the second-generation sequencing data, obtaining several HLA typing results; combining these with reference sequencing data to determine the performance evaluation results of each HLA typing tool; screening and optimizing HLA typing tools; and finally, obtaining the final HLA typing result. This invention, through data-driven tool optimization and gold standard validation, significantly improves the accuracy, reliability, and ability to discover new risk alleles in HLA typing in complex disease contexts, effectively reducing the cost of large-scale research, and has significant value for the study of the genetic mechanisms of autoimmune diseases and precision medicine.

IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.